News

FDA Grants QIDP Fast-Track Designation to RedHill Biopharma’s Phase III H. pylori Drug RHB-105

FDA Grants QIDP Fast-Track Designation to RedHill Biopharma’s Phase III H. pylori Drug RHB-105   FDA Grants QIDP Fast-Track Designation to RedHill Biopharma’s Phase III H. pylori Drug RHB-105 – Hebrew

Read More...

RedHill Biopharma Reports Results for the Third Quarter of 2014

RedHill Biopharma Reports Results for the Third Quarter of 2014   RedHill Biopharma Reports Results for the Third Quarter of 2014 – Hebrew

Read More...

RedHill Biopharma to Host Third Quarter 2014 Financial Results Conference Call on November 10, 2014

RedHill Biopharma to Host Third Quarter 2014 Financial Results Conference Call on November 10, 2014

Read More...

RedHill Biopharma to Present at the 20th Annual BIO-Europe International Partnering Conference

RedHill Biopharma to Present at the 20th Annual BIO-Europe International Partnering Conference

Read More...

RedHill Biopharma and IntelGenx Submit European Marketing Authorization Application for Migraine Drug RIZAPORT (formerly RHB-103)

RedHill Biopharma and IntelGenx Submit European Marketing Authorization Application for Migraine Drug RIZAPORT (formerly RHB-103)   RedHill Biopharma and IntelGenx Submit European Marketing Authorization Application for Migraine drug RIZAPORT (formerly RHB-103) – Hebrew

Read More...

RedHill Biopharma to Present at the 14th Annual Biotech In Europe Forum for Global Partnering & Investment

RedHill Biopharma to Present at the 14th Annual Biotech In Europe Forum for Global Partnering & Investment

Read More...

RedHill Biopharma to Present at the 7th Annual BioPharm America International Partnering Conference

RedHill Biopharma to Present at the 7th Annual BioPharm America International Partnering Conference

Read More...

RedHill Biopharma to Present at the Rodman and Renshaw 16th Annual Global Investment Conference

RedHill Biopharma to Present at the Rodman and Renshaw 16th Annual Global Investment Conference

Read More...

RedHill Biopharma Initiates Phase III Study of RHB-102 for Gastroenteritis

RedHill Biopharma Initiates Phase III Study of RHB-102 for Gastroenteritis   RedHill Biopharma Initiates Phase III Study of RHB-102 for Gastroenteritis – Hebrew  

Read More...

RedHill Biopharma Provides Update on Expansion of Ongoing RHB-105 Phase III Study, Targeting Broadened H. pylori Indication Authorized by FDA

RedHill Biopharma Provides Update on Expansion of Ongoing RHB-105 Phase III Study, Targeting Broadened H. pylori Indication Authorized by FDA   RedHill Biopharma Provides Update on Expansion of Ongoing RHB-105 Phase III Study Targeting Broadened H. pylori Indication Authorized by FDA – Hebrew

Read More...

News